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Background: Psychological interventions are increasingly recommended as adjunctive treatments for psychosis,
but their implementation in clinical practice is still insufficient. The individualized metacognitive therapy program
(MCT+; www.uke.de/mct_plus) represents a low-threshold psychotherapeutic approach that synthesizes group
metacognitive training (MCT) and cognitive behavioral therapy for psychosis, and addresses specific cognitive biases
that are involved in the onset and maintenance of psychosis. It aims to “plant the seed of doubt” regarding rigid
delusional convictions and to encourage patients to critically reflect, extend and change their approach to problem
solving. Its second edition also puts more emphasis on affective symptoms. A recent meta-analysis of metacognitive
interventions (MCT, MCT+) indicate small to moderate effects on positive symptoms and delusions, as well as high
rates of acceptance. Nonetheless, no long-term studies of MCT+ involving large samples have been conducted.
Methods: The goal of the present multi-center, observer-blind, parallel-group, randomized controlled trial is to
compare the efficacy of MCT+ against an active control (cognitive remediation; MyBrainTraining©) in 328 patients with
psychosis at three time points (baseline, immediately after intervention [6 weeks] and 6 months later). The primary
outcome is change in psychosis symptoms over the 6-month follow-up period as assessed by the delusion subscale of
the Psychotic Symptom Rating Scale. Secondary outcomes include jumping to conclusions, other positive symptoms
of schizophrenia, depressive symptoms, self-esteem, quality of life, and cognitive insight. The study also seeks to
elucidate mediating factors that promote versus impede symptom improvement across time.
Discussion: This is the first multi-center randomized controlled trial to test the efficacy of individualized MCT+ in a
large sample of patients with psychosis. The rationale for the trial, the design, and the strengths and limitations of the
study are discussed.
Trial Registration: The trial is registered through the German Clinical Trials Register (www.drks.de) as DRKS00008001.
Registered 6 May 2015.
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Schizophrenia remains a stigmatizing and chronic dis-
order that affects approximately 1 % of the population
worldwide and is among the world’s top ten causes of
chronic disability [1]. Due to the poor quality of life
among many of those affected [2] and the large health-
care costs incurred through repeated hospitalizations
[3], improved treatment for schizophrenia is needed.
Although antipsychotic medications remain the treat-
ment of choice for schizophrenia, up to 60 % of patients
do not respond to antipsychotic medications [3] and
rates of non-adherence are as high as 60 % within the
first year of treatment [4]. Furthermore, among those
who are compliant with medications, a minority (ap-
proximately 40 %) have a good symptomatic outcome
and recovery rates are only around 20 %. Moderate
effect sizes have been reported for improvement in
positive symptoms relative to placebo; however, non-
pharmacological approaches are also necessary to treat
cognitive symptoms, such as cognitive biases [5–7].
Given the limitations to treatment with antipsychotic
medications alone, there has been increasing interest in
developing alternative interventions for psychosis, and
particularly adjunctive psychotherapies have been inte-
grated as a core element of international treatment
guidelines [8]. Cognitive behavioral therapy for psychosis
(CBTp) [9–12] and cognitive remediation (CR) [13]
represent two such psychotherapeutic approaches, which
have yielded small to medium effects beyond anti-
psychotic medications. While CBTp aims to identify
pathological symptoms and change dysfunctional cogni-
tive processes, CR focuses on improvement of deficits in
basic neuropsychological functioning (i.e., memory, ex-
ecutive functioning attention) through computerized or
paper-and-pencil exercises. Despite the promising sup-
port for these interventions and evidence that patients
with psychosis are responsive to psychotherapy, a major-
ity of patients never receive empirically-based treatments
(EBTs) ([14, 15], Moritz S, Berna F, Jaeger S,
Westermann S, Nagel M. The customer is always right?
Subjective target symptoms and treatment preferences in
patients with psychosis, submitted.) due to a number of
patient (e.g., stigma, shame) and organizational barriers.
Among those patients who do seek treatment, many must
wait several months before they can begin therapy due to
limitations in insurance reimbursement or therapist avail-
ability. Additionally, while therapists and family members
identify positive symptoms as a main treatment goal, pa-
tients tend to prioritize rather quality of life and affective
symptoms [(Moritz S, Berna F, Jaeger S, Westermann S,
Nagel M. The customer is always right? Subjective target
symptoms and treatment preferences in patients with
psychosis, submitted) 16, 17]. As such, lack of agreement
on treatment goals between therapists and patients mayalso contribute to poorer therapy adherence and satisfac-
tion. At the organizational level, therapists cite a lack of
funding to gain necessary training, as well as negative staff
attitudes toward EBTs. Many therapists feel that they do
not have sufficient time to appropriately implement EBTs,
despite adequate training [15]. As such, there is need for ef-
fective low-intensity interventions, which can increase
treatment accessibility for patients with psychosis [18].
The current study is designed to test the effectiveness
of an innovative treatment for psychosis, the individual-
ized metacognitive therapy program (MCT+), compared
to an active control group, which completes cognitive
remediation. The group version of the treatment pro-
gram, metacognitive training (MCT) was developed by
Moritz and colleagues in 2002/2003 and adopts a
metacognitive perspective (i.e., “thinking about one’s
thinking”). The MCT approach is based on significant
evidence from many research groups [19–25], including
our own [26–29], that cognitive biases underlie the
formation and maintenance of schizophrenia. While
patients are often unaware of these cognitive biases (such
as overconfidence, incorrigibility and hasty decision-
making), they are not limited only to delusional beliefs,
but can also be observed in daily delusion-neutral situa-
tions. As discussed in recent publications [30, 31], MCT
aims to “plant the seed of doubt” regarding delusions
through corrective (“aha!”) experiences in an entertaining,
playful and collaborative manner. In this way, MCT aims
to raise patients’ awareness regarding the negative impact
of cognitive biases, which contribute to the pathogenesis
and perpetuation of positive symptoms.
The intervention borrows from CBTp, CR and psy-
choeducational approaches by focusing on symptoms,
presenting multiple cognitive exercises and providing
general information on the disorder. However, differing
from CBTp, MCT adopts a “backdoor” approach in
which general cognitive processes are first addressed
before examining how these biases may lead to problems
in everyday life and psychotic symptoms, respectively.
Additionally, rather than focusing on accuracy and
traditional neuropsychological faculties (e.g., memory,
attention) as in CR, MCT particularly attempts to
attenuate participants’ overconfidence in errors (e.g., by
asking patients to consider their level of certainty before
making a final decision) and delay decision-making for
momentous judgments. Therefore, the goal of MCT is
not to dissuade patients from their delusional thoughts,
but to promote doubt regarding the likelihood that the
delusional thought content accurately reflects reality.
The individualized version of MCT, termed MCT+,
was recently developed to allow for more detailed tar-
geting of patient-specific problems, which cannot be
addressed in group therapy [32, 33]. Importantly, over-
coming the above-mentioned barriers to psychotherapy,
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based mechanism of action, and although it is highly
structured and fully manualized, the therapist can select
the therapy units that fit best to the patient’s current dif-
ficulties and cognitive biases. Based on patient feedback
and research findings that patients wish to prioritize
treatment of affective symptoms, in the newest edition,
more focus has been placed on affective symptoms. Like
the group variant, in MCT+ therapists first teach partici-
pants about cognitive biases and dysfunctional emotional
regulation before individual problems are addressed. To
increase the dissemination and use of MCT and MCT+;
materials are available for free in many world languages.
The group MCT is available in 33 language versions and
MCT+ is currently available in 10 versions.
As summarized in a comprehensive review [30], the
feasibility, safety and efficacy of group MCT has been
demonstrated in several study trials. The intervention is
well-accepted by patients, who indicate that they find
the training to be fun and would recommend MCT to
others [30, 34, 35]. A recent meta-analysis [35] revealed
that MCT yields significant small to moderate effects on
positive symptoms (g = .34) and delusions (g = .41) in
comparison to control conditions and that effects are
higher for the three completed trials of individualized
MCT (positive symptoms: g = −0.53; delusions: g = −0.26).
However, it is important to point out that two of the stud-
ies included in these analyses utilized the materials for
group MCT in an individualized setting [36–38]. There-
fore, there has been only one trial of MCT+ [34], which
yielded small to moderate significant improvements
(ηpartial
2 = .10) in delusions and positive symptoms com-
pared to an active control group. Despite the overall posi-
tive effects, notably, one large trial by van Oosterhout and
colleagues (2014) found no superiority for group MCT
compared to a treatment-as-usual (TAU) control group for
symptoms. Although the reasons for this “outlier” remain
unclear, the study included patients with moderate to se-
vere delusions and used an older version of group MCT,
which did not highlight the role of (over) confidence. While
the training is aimed at improving positive symptoms, clin-
ical experience indicates that patients with acute symptoms
often have difficulty engaging in the group setting and have
limited ability to acknowledge cognitive biases. Therefore,
it is now recommended that trainers screen out such pa-
tients for the group intervention. Such patients may be
more amenable to MCT+ as the individualized setting is
more flexible and allows more time for addressing such
acute symptoms. Additionally, the earlier version of MCT
did not include as much focus on attenuating confidence
in the face of incomplete or ambiguous evidence, which is
now a core component of the training. Despite the pos-
sible explanations for these null findings, it must also be
considered that MCT is not helpful for all patients [39].While some studies have demonstrated significant im-
provements in cognitive biases (especially jumping to
conclusions or data gathering) thought to be implicated
in delusional ideation [40–45], others have not been able
to find significant differences [36, 46, 47] in comparison
to active control and wait-list groups. Recent studies re-
vealed significant improvements in cognitive insight for
MCT compared to an active control group [48] and a
wait-list control group [46]; however, no significant
differences were reported in the van Oosterhout et al.
trial. One trial found a significant group difference for
improvement in social functioning [49]; however, in this
study, MCT was combined with social cognition
training.
Despite these promising findings, the long-term effects
of MCT and particularly MCT+ remain largely un-
known. In one recent MCT trial, improvement on the
PSYRATS was sustained for up to three years, and
“sleeper effects” for self-esteem and global quality of life
emerged only at the three year follow-up [47]. Nonethe-
less, there has only been one trial of MCT+, which was
small (n = 48) and did not involve follow-up assessment.
Moreover, MCT+ has been updated since this study and
now includes more focus on affective symptoms and
stigma. A large trial is also needed to elucidate for which
symptom domain MCT+ is the most helpful and symp-
toms or demographic constellations (e.g., age, gender,
education) that may moderate outcome.
Aims of the trial
The primary aim of this study is to investigate the
effectiveness of MCT+ versus computerized cognitive
remediation (CR; MyBrainTraining©) in individuals with
psychosis.
The primary research question is:
1) Does MCT+ result in a greater reduction in
rater-observed symptoms of delusions, as measured
by the Psychotic Symptom Rating Scales (PSYRATS
delusions subscale), compared to computerized CR at
the end of treatment (6 weeks)?
Secondary research questions are:
2) Does MCT+ result in a greater reduction in other
positive, negative and affective psychopathology than
computerized CR as measured by the Positive and
Negative Symptoms Scales (PANSS)?
3) Does MCT+ result in a greater reduction in jumping
to conclusions than computerized CR? Is change in
jumping to conclusions associated with
improvement in positive symptoms?
4) Does MCT+ result in a greater reduction in
self-reported symptoms of depression and/or a greater
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insight than computerized CR?
5) Does computerized CR result in a greater improvement
in neuropsychological functioning than MCT+?
6) Are baseline characteristics or therapy motivation
predictive of treatment response to MCT+?
Although small, yet significant, decreases in psychosis
symptoms have been reported in some studies of CR in-
terventions [13], based on previous work, we hypothesize
that MCT+ will lead to a greater decrease in delusions as
compared to patients in the computerized CR group at
post and follow-up test sessions (Q1). Cognitive remedi-
ation is deemed an appropriate comparison group for the
present study since its feasibility has been asserted, and
because it offers some amelioration of neuropsychological
symptoms, but does not address cognitive biases at the
core of MCT+. We further hypothesize that, compared to
the control group, we will find a greater reduction in the
PANSS positive syndrome [50] at the same time points for
MCT+ participants (Q2). Given previous mixed results re-
garding improvement in jumping to conclusions [30, 51],
we hypothesize that data gathering will improve in both
groups, but that only improvement in the MCT+ group
will be significantly associated with improvement in delu-
sions (Q3). Because the newest version of MCT+ places
more focus on affective symptoms and significant (sleeper)
effects have already been detected for quality of life and
self-esteem in group MCT (which did not include these
new therapy units), we anticipate that participants who
complete MCT+ will demonstrate improvements in de-
pressive symptoms, quality of life and self-esteem, which
are superior to the control group (Q4). As mentioned
above, a limited number of previous studies have yielded
mixed findings regarding the effects on cognitive insight.
Therefore, we do not expect changes in this domain. Tri-
als on CR programs, as well as our own work, suggest that
CR exerts a small to moderate effect on neurocognition
[47, 52]. Therefore, it is expected that participants in the
control group will experience greater improvements in
neuropsychological functioning than those in MCT+ (Q5).
Finally, we posit that participants with greater therapy mo-
tivation will have a better response (i.e., greater decrease in
delusions) to MCT+ (Q6). Based on previous MCT trials
[53], we hypothesize that participants with symptoms in
the moderate range will benefit most from MCT+.
Methods/Designs
Study design
The design of the study is a multi-center, assessor-blind,
parallel group, randomized controlled trial. Patients will
be randomized to MCT+ or computerized CR. The
study protocol has been approved by the German Psy-
chological Society (Deutsche Gesellschaft für Psychologie;SM_102015_amds_div), as well as by local ethics
committees (Medical Faculty of the Ruhr-University
Bochum; Medical Faculty Mannheim of the University
of Heidelberg and University Hospital Mannheim). It
has been registered at the German Registry for Clinical
Studies under the number DRKS00008001.
Participants
The study population will consist of individuals with
psychosis (as confirmed by the Mini International
Neuropsychiatric Interview, 5th Ed [M.I.N.I.]) [54].
Diagnoses according to the Diagnostic and Statistical
Manual of Mental Disorders – 5th edition (DSM-5) [55]
are then derived from information gained from the
M.I.N.I. To enhance recruitment and generalizability,
the study is being conducted in four different German
clinics for patients with psychosis: the Department of
Psychiatry and Psychotherapy at the University Medical
Center Hamburg-Eppendorf, the Department of Psychiatry
and Psychotherapy at the Central Institute of Mental
Health in Mannheim, the Clinic for Psychiatry,
Psychotherapy and Preventative Medicine at the LWL
University Hospital Bochum, and the Clinic for Psychiatry
and Psychotherapy at the Asklepios Clinic North in
Hamburg-Wandsbek. Each center has specialized out-
and inpatient clinics for treatment of psychosis.
Eligibility criteria
Generalizability of study results is of main importance;
therefore, eligibility criteria were chosen to recruit a broad
sample representative of the population of patients with
psychosis. Participants between the ages of 18 and 65 who
meet the following criteria will be included in the
study: a) primary diagnosis of psychosis as verified by the
M.I.N.I. and supplemented by diagnostic criteria for
schizophrenia and schizoaffective disorder from the DSM-
5; b) provide informed consent; c) sufficient understand-
ing of the German language. Exclusion criteria include: a)
IQ < 70 (according to a premorbid intelligence vocabulary
test); b) PANSS scores ≥ 5 for hostility and non-
cooperativeness (G8, P7); c) endorsement of suicidal intent;
d) current alcohol or substance dependence (abstinence
must be > 6 months), excluding tobacco; e) any form of
documented or suspected major neurological or general
medical condition that might be responsible for the
psychotic manifestations; f ) participation in MCT+
within the past 12 months.
Procedure and treatment allocation
Recruitment occurs in different ways: recruitment by
study staff during inpatient stays, referrals from mental
health professionals at clinics both within the cooperat-
ing centers and in the community (including private
practices), and by self-selection through advertisements
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for schizophrenia treatment in the community. Interested
patients receive an informational leaflet and undergo a
screening interview by telephone or in-person with re-
search assistants to assess eligibility. If patients appear
eligible upon initial contact, they are invited for baseline
testing in which informed consent is obtained (or it is
obtained before testing for patients with guardians for
medical decision-making).
Blinded in-person assessments conducted by trained
study research assistants, psychologists or psychiatrists
are performed at baseline, 6 weeks and 6 months after
baseline (see Table 1). All raters complete a rater-
training workshop and also receive individual training in
which they are observed as the measures are adminis-
tered. The 6-week intervention phase begins directly
after completion of baseline testing. To diagnose or con-
firm the diagnosis of psychosis or an affective disorder
with psychotic features, as well as to rule-out acute
suicidality and substance dependence, a semi-structured
interview with the M.I.N.I. is completed with all patients
at baseline and 6-month sessions. A questionnaire for
intervention group preference and motivation is com-
pleted at the beginning of the first treatment session.
Questionnaires assessing participants’ acceptance of both
interventions are completed at post and follow-up. The
sociodemographic interview and all other measures,
including semi-structured interviews for schizophrenia
symptoms (PANSS and PSYRATS), self-report question-
naires, and neuropsychological measures are completed
at all three testing sessions (see Table 2 for list of mea-
sures and administration time points).
A measure was developed by the authors (BS, FB, SM)
to assess therapist adherence to the MCT+ manual. For













Follow-upare video recorded and psychologists familiar with
MCT+ assess adherence. Additionally, questionnaires
developed by the authors (SM) assessing participants’
acceptance of both interventions are completed after
every training session attended.
Participants are allowed to use antipsychotic medica-
tions during the entire study and are not withheld from
other psychosocial treatments they might be offered or are
currently participating in, including participation in MCT
group therapy. Participation in concurrent interventions is
recorded at post- and follow-up testing sessions. Partici-
pants are allowed to withdraw from intervention or as-
sessment sessions upon request without having to disclose
a reason. All participants are compensated with 30€ upon
completing of each assessment session.
Randomization and assessor blindness
Treatment allocation is randomized via a computerized
randomization plan (no stratification factors) and per-
formed observer-blind. Extensive steps are taken to
ensure rater blindness. The randomization plan is only
accessible to the study coordinators, thus reducing the
risk that assessors may be accidentally unblinded.
Patients are informed that they are not to disclose their
group assignment and are reminded of this at every test-
ing session. At the end of the baseline testing session, all
participants meet with a member of the research team
who is not involved in testing and has access to the
site-specific randomization list. This individual gives
the participant an envelope in which intervention as-
signment is identified. Raters are not involved in the
active intervention. Rater blinding is verified by ask-
ing the rater to guess the participant’s treatment allo-
cation at the beginning of every testing session and
indicating their certainty.Study period






Table 2 List 1 of study measures and questionnaires
Instrument Baseline 6 weeks (post) 6 months (follow-up)
Diagnostic and Measures of Psychopathology
Sociodemographic interview X X X
Mini Neuropsychiatric Interview X X
Positive and Negative Syndrome Scale X X X
Psychotic Symptom Rating Scales X X X
Calgary Depression Rating Scale X X X
Personal and Social Performance Scale X X X
Negative Symptom Assessment – 4 X X X
Neurocognitive Measures
Trail Making Test A & B X X X
Test d2 X X X
German Vocabulary Test (premorbid intelligence) X
Rivermead Behavioural Memory Test, Story Recall X X X
Cognitive biases
Fish Test X X X
Questionnaires
Short Form-12 X X X
Patient Health Questionnaire X X X
Beck Cognitive Insight Scale X X X
Rosenberg Self-Esteem Scale X X X
Evaluation of the Intervention X X
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Selection and diagnostic measures The Mini-
International Neuropsychiatric Interview 5.0 (German
version) [54], a short, structured diagnostic interview
based on DSM-5 criteria, will be conducted to assess spe-
cifically for psychosis, affective disorder with psychotic
features, substance use disorders and suicidality. It is fully
structured to allow administration by non-specialized
interviewers. The agreement between the M.I.N.I. and the
Structured Clinical Interview for DSM-IV (SCID) is good
or very good for most diagnoses. Test-retest reliability is
also good (kappa = .75).
Primary outcome measure The PSYRATS is a com-
monly used semi-structured interview that measures
quantitative and qualitative aspects of delusions and
hallucinations, including preoccupation, conviction and
distress. The difference in PSYRATS delusions subscale
score from baseline to follow-up serves as the primary
outcome parameter. The validity of the PSYRATS has
been demonstrated in chronically psychotic patients and
it has been shown to have good psychometric properties
[56]. Unlike the PANSS, which collapses important as-
pects of positive symptoms (e.g., delusion conviction and
distress), the PSYRATS allows for a multivariateassessment of delusions and, the PSYRATS is highly cor-
related with the PANSS.
Secondary outcome measure
1) The Positive and Negative Symptoms Scale (PANSS)
is a 30-item scale that assesses positive, negative and
general psychopathology based on a semi-structured
interview. The PANSS has good psychometric
properties and is sensitive to change [57].
2) The Fish Task [58] is a computerized variant of the
classical Beads Task. In this measure, participants
are shown two lakes containing orange and gray fish
(e.g., lake A with 80 % orange and 20 % gray fish,
and lake B with the reverse ratio). Ten fish are
successively presented in a predetermined sequence
to the participant. After each draw, the participant
indicates whether they can make a decision
regarding the origin of the fish. All fish drawn
remain visible throughout the task in order to
minimize working memory demands. Parallel
versions are used across the testing sessions to
reduce practice effects. The presence of a jumping
to conclusions bias is defined as reaching a decision
after drawing only one or two fish. The key variable
of interest is the number of draws to decision.
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an instrument to rapidly assess negative symptoms
based on a rating by the interviewer, which includes
four items (restricted speech quantity, reduced
emotion, reduced social drive, and reduced interests).
Each item is rated by the interviewer on a scale from
‘1’ to ‘6’ where ‘1’ represents no reduction from
normal behavior and ‘6’ represents severe reduction
in or absence of the behavior, with markedly impaired
functionality. Consistency of ratings by experts has
been shown to be high [60].
4) The Patient Health Questionnaire-9 item (PHQ-9)
[61] is a self-report measure of depression, which is
a module of the full Patient Health Questionnaire.
Each item is rated based on the presence or absence
of the symptom over the past 2 weeks for a total
possible score of 27. Mild depression is likely at a
score of 5, while the cutoff for severe depression is
15. Internal reliability (Cronbach’s α = .89) and
test-retest reliability (r = .84) of the scale are excellent.
5) The Calgary Depression Scale for Schizophrenia
(CDSS) [62] is a brief semi-structured interview
scale, which allows raters to assess depressive
symptoms separate from positive, negative and
extrapyramidal symptoms in people with
schizophrenia. The nine items of the scale are rated
on operational criteria from ‘0’ to ‘3’. The scale is
correlated with other depression rating scales
(Hamilton Depression Rating Scale and the Beck
Depression Inventory). Internal reliability is good
(Cronbach’s α = .79) [63].
6) The World Health Organization Quality of
Life - BREF (WHOQOL-BREF) [64, 65] is a self-
report measure of overall life satisfaction. The
measure assesses quality of life in four domains:
physical, psychological, social and environment.
Internal consistency assessed internationally
across several study centers for most scales is
good (Cronbach’s α > .70).
7) The Rosenberg Self-Esteem Scale (RSE) [66] is a
widely used 10-item self-report measure that
assesses global self-esteem. Internal consistency
(Cronbach’s α = .84) as well as split-half reliability
(r = .74) of the German version are good.
8) The Beck Cognitive Insight Scale (BCIS) [67]
measures self-reported ability to distance oneself
from and reflect upon subjective cognitive biases.
The 15-item measure is comprised of two subscales:
self-reflectiveness and self-certainty. Insight plays an
important role in the formation and maintenance of
psychotic symptoms. Internal consistency among
individuals with schizophrenia is acceptable
(Cronbach’s α = .60 – .68). In Beck’s initial study,
the mean self-reflectiveness score for patientswithout a psychosis diagnosis did not significantly
differ from those without a psychosis diagnosis
while self-certainty was higher among those with a
psychosis diagnosis in comparison to patients
without a psychosis diagnosis [67].
9) The Personal and Social Performance Scale (PSP)
[68] is a semi-structured clinician-rated interview
of social functioning over the past 30 days in
individuals with schizophrenia. The PSP rates
functioning on four subscales: socially useful
activities, personal and social relationships, self-care,
disturbing and aggressive behavior. Descriptive
anchor points (I = absent; VI = very severe) are used
to rate patient functioning in these domains. An
overall functioning score is then derived from the
subscale scores. Inter-rater reliability is acceptable
(Cohen’s κ = .68).
10)The Short Form-12 (SF-12) [69] is a short
self-report questionnaire used to measure functional
health and well-being. The SF-12 has been shown
to distinguish individuals with severe mental illness
from the general population. Psychometric
properties of the scale, including test-retest
reliability and convergent and divergent validity
among individuals with severe mental illness are
supported [70].
Additionally, to characterize the sample and assess
change in neuropsychological functioning, neuropsy-
chological assessment measures will be administered,
including the Trail Making Tests A and B (mental flexibil-
ity, set-shifting) [71], Test d2 (selective attention) [72],
Story Recall subtest of the Rivermead Behavioural Memory
Test (short- and long-term verbal memory) [73], and
the German Vocabulary Test (Wortschatztest; premor-
bid intelligence) [74].
Intervention
To ensure comparability of results, both interventions
are implemented for the same duration (6 weeks; 12
sessions) and frequency (45–60 min per session). Psy-
chologists undergoing post-graduate training provide
both MCT+ and computerized CR. All MCT+ trainers
completed a 2-day MCT+ workshop and receive regular
intervision from two of the authors of the MCT+ ther-
apy program (RV, FB).
Individualized metacognitive therapy program (MCT+)
The main aim of MCT+ is to “plant the seed of doubt”
regarding rigid delusional convictions and to encourage
patients to critically reflect, extend and change their ap-
proach to problem solving. Importantly, patients are not
to be “talked out” out their symptoms as this can lead to
an escalation of cognitive biases and, thus, increased
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an individualized plan for addressing symptoms and
cognitive biases is formulated based specifically on each
patient’s presenting problems and goals. The second
edition of the German manual by Moritz et al. was
provided to all study trainers (MCT+ materials can be
obtained by contacting the authors) [75]. The major
changes to the updated manual are the addition of ele-
ments regarding stigma and of a new unit focused on
self-esteem. An overview of the MCT+ units is provided
in Table 3. All of the MCT+ therapy units that focus on
cognitive biases (i.e., Therapy Unit 4: Attributional Style;
Therapy Unit 5: Decision Making; Therapy Unit 6:
Changing Beliefs; Therapy Unit 7: Empathizing; Therapy
Unit 8: Memory and Certainty of Judgment) first high-
light the fallibility of cognition in general and discuss
specific problematic exaggerations of these cognitive
processes in individuals with schizophrenia. In a second
step, the relationship between cognitive biases, symp-
toms and their consequences for everyday life, as well as
the course of the illness, are emphasized.
Although the MCT+ units are presented in the order
provided in Table 3, it is emphasized that treatment
should be tailored to the individual needs and insight
level of the patient, as well as trainer preferences. As
such, more time can be spent on any one unit and
themes can be skipped completely. For the purposes of
the RCT, all trainers were instructed to complete the
first therapy units focused on discussion of the im-
portance of trust and openness to the therapeutic
relationship and taking a case history (Therapy Unit 1),
introducing MCT+ (Therapy Unit 2) and developing a
personal illness model (Therapy Unit 3; when appropri-
ate, this unit can also be completed at a later stage
during therapy). In addition, trainers are to choose at
least two units addressing cognitive biases. There are
also two units devoted to affective problems (Therapy
Unit 9: Depression and Thinking; Therapy Unit 10:
Self-Esteem). In the last unit, focus is on coping with
(the stigma of ) illness, preparing patients for the
discontinuation of therapy and discussing relapse pre-
vention strategies (Therapy Unit 11). Each unit in-
cludes a number of therapy demonstrations, as well
as worksheets displaying discussion topics and exer-
cises that serve to illustrate the main topic. Certain
exercises (e.g., card trick in Therapy Unit 4) are pref-
erably presented with the help of a computer laptop
or tablet.
In addition, most sessions include “between-session”
tasks (i.e., homework) to encourage application and
practice of skills in daily life. Homework is then dis-
cussed at the beginning of the following session. Given
that many patients with psychosis have difficulties
remembering and organizing information, in the lastsession participants are given a booklet of copies of im-
portant MCT+ therapy demonstration sheets that were
presented during the treatment so that they have a “self-
help” booklet to review after therapy has ended. Add-
itionally, postcards are sent to the participants three
months after the final session to inquire whether they
have been using the skills learned in MCT+. Although
participants are not allowed to respond to the mailing,
they are encouraged to look at their booklets and review
the MCT+ materials.
Cognitive remediation MyBrainTraining© (BBG Enter-
tainment GmbH) [76] is a newly developed computer-
based cognitive remediation program, which aims to
improve cognitive functioning deficits present in schizo-
phrenia by presenting a series of cognitive exercises,
which are repeatedly practiced. In the present study, par-
ticipants complete all exercises independently. The pro-
gram consists of thirty exercises aimed at training
executive functioning through different types of tasks,
including those of vision, arithmetic, logic and memory.
All exercises are conducted on PC’s over the Internet.
The exercises were designed during the development of
the “Train your Brain with Dr. Kawashima” program in
cooperation with the Industry University Research Pro-
ject and Professor Dr. Ryuta Kawashima.
Based on the participant’s performances, the difficulty
of each task automatically increases or decreases. The
exercises are similar to video games and include fun or
motivational elements. The administrator has the ability
to determine specific training plans and to adapt exer-
cises to each patient’s needs (e.g., level of difficulty, var-
ied time limits, etc.). Data protection and security
comply with industry standards.
For the present study, participants are asked to
complete the exercises in a specific order and are
provided with feedback from the program on their per-
formance, which they record on an exercise log. Log-in
information is not shared with participants to prevent
practice at home. Like the MCT+ group, three months
after the final session participants are sent a postcard
asking if they are still using the skills learned while com-
pleting MyBrainTraining© and if they have continued
cognitive exercises using other modalities (e.g., cross-
word puzzles, Sudoku, etc.).
Sample size
This is the first trial of MCT+ in which participants are
followed for a longer period after completion of treat-
ment. As such, determination of optimal sample size
was based on an initial trial of MCT+ [34], which in-
cluded 48 patients and yielded medium to large effect
sizes (ɳpartial
2 = .08 – .13) compared to cognitive remedi-
ation (CogPack©). In this pilot study, non-compliance
Table 3 MCT+ therapy units
Unit Description Exercise/Therapy worksheet examples
1. Case History Questionnaire The patient’s case history including current problems and
symptoms, as well as previous treatments, are gathered
through a clinical interview. The patient’s level of
motivation is evaluated and the importance of the
therapeutic relationship is discussed.
With the use of worksheets, the therapist and patient
identify the patient’s current problems, including
delusions or hallucinations and to what extent the
patient is certain of this belief. Interpersonal or coping
difficulties resulting from the delusion/hallucination are
identified.
2. Introduction to MCT+ Information about MCT+ and the main therapeutic
strategies are discussed. A secondary goal is to develop
an understanding of the patient’s problem areas and
possible therapeutic targets.
An overview of the therapy program is provided and the
patient’s goals are determined with help from therapy
worksheets. Patients are asked to identify current or past
symptoms and how distressed they are (have been) by
these symptoms.
3. Case Formulation An individual vulnerability-stress-model is created utilizing
a “fire” metaphor. For patients with limited illness insight
who may be overwhelmed by such a discussion or may
be unable to accept explanations for their symptoms, this
therapy unit can also be completed toward the end of
the training.
Using therapy worksheets the “fire” metaphor is
personalized. Vulnerability factors (e.g., genetic
predisposition) are compared to wood or coals, while
factors that contribute to a first psychotic episode (e.g.,
stress), are likened to a spark, which ignites the flames.
Interventions, which help to reduce symptoms (e.g.,
psychotherapy), are the “fire extinguisher.”
4. Attributional Style The goal is to help patients understand that complex
social situations can rarely be attributed to one cause
(i.e., mono-causal attributions), but are rather the outcome
of many factors (myself, other people, circumstances).
It is important to help patients gain insight to situations
in which they themselves tend to make one-sided
attributions, and how certain attributions (especially
personalization and blame) reinforce delusions.
Using fictional and, if possible, personal real-life examples,
patients are encouraged to identify multiple causes of
events that may otherwise be attributed to psychosis-
related factors (e.g., a strange smell means that I am being
poisoned rather than the possibility that there was a
chemical spill or I am in an unfamiliar area where smells
may be new). A “card trick” exercise is used to illustrate that
there are often simple explanations for strange experiences.
5. Decision Making Jumping to conclusions can lead to suboptimal
decisions, sometimes with dramatic consequences.
Patients are encouraged to reflect on whether they
currently, or in the past, have made decisions too hastily,
and if their delusions were caused or strengthened by
these “short-circuit” thinking patterns. Patients should
learn to consider the pros and cons of making strong
assumptions and to always be open to alternative
explanations.
Patients are shown, for example, slides of line drawings in
which the details of the figure become increasing clear
with each slide. The patient is asked to indicate when
they are certain that they know what is depicted. Early
responses are often incorrect as not enough details are
present to reach a clear decision.
6. Changing Beliefs Being stubborn and inflexible at times is part of human
nature and can actually be helpful to ensure a certain
amount of stability so that we do not instantly question
everything and everyone. However, being overly fixated
can lead to problems too, especially if one’s convictions
are wrong.
Pictures, which depict a story, are shown to the patient
in reverse order (i.e., the last pictures is shown first). The
patient is asked to indicate when they are certain that
they know the correct beginning of the story. Often
reaching a decision with incomplete information leads to
an incorrect response.
7. Empathizing “To err is human”, especially when it comes to assessing
the motives of others. It is emphasized that we cannot
infer what another person’s emotional state is from facial
expressions or nonverbal signals alone. To become more
certain about our interpretation, patients are encouraged
to consult additional sources (e.g., contextual factors,
previous knowledge of the person). Patients learn that
social perceptions are often influenced by personal
feelings and people often tend to confuse their inner
emotional world with the outside world (e.g., when
anxious, a patient may think: “Everybody is against me”).
"Unwritten social rules” are also discussed with the
patient. The relationship to delusions should be carefully
clarified.
The patient is shown a series of pictures and is asked to
guess how the person is feeling or what they are
thinking. It is emphasized that it is often difficult to know
how another person is feeling and that additional
information should be sought to avoid making incorrect
assumptions. The patient is asked to identify situations in
which they were uncertain of how others were feeling.
8. Memory and Certainty of
Judgment
The potential for memory biases are discussed and
normalized. It is always important to consider the
possibility that vague memories might be false, and
therefore, should be investigated further by asking others
or consulting documents as false memories can have
potentially serious consequences (e.g., conflict).
Patients are briefly shown complex scenes with many
objects and are then asked to identify which objects
were present in the scene. It is discussed with the patient
that, like all humans, their memory may not always be
perfect and details are often added or omitted based on
previous experiences or “common sense” (i.e., false
memories).
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Table 3 MCT+ therapy units (Continued)
9. Depression and Thinking This unit focuses on improving self-perceptions and
improving or maintaining social relationships with others.
Depression is not “unavoidable” or innate, but tends to
be promoted and maintained through certain thought
distortions, which can be changed. Therapists help
patients to become more aware of if and when they
tend to have depressive thought distortions and how
their personal depressive symptoms or delusions were
intensified or perhaps caused by such thoughts. The
extent to which psychosis has an effect on self-esteem is
also discussed.
With the help of fictional and, if possible, personal
real-life examples, patients are asked to identify alternative,
more helpful thoughts for various situations when one
might use “black and white thinking” or “should”
statements (e.g., when receiving negative
feedback from a boss).
10. Self-Esteem Self-esteem is defined in MCT+ as something that one
largely subjectively determines and actually has little to
do with the opinions of others. The therapist carefully
addresses the different influences that psychotic
symptoms can have on one’s self-esteem (excitement
and a feeling of being important versus anxiety and
guilt), while also recognizing that these symptoms can
also partially serve a social function. Using the metaphor
of an “inner critic” and a “well-meaning companion,” it is
carefully suggested that sometimes content from
auditory hallucinations can reflect inner conflicts.
The patient is encouraged to identify personal strengths,
especially in areas, which are often not noticed or
thought of as self-evident. Concrete situations in which
these strengths have been demonstrated are identified.
11. Dealing with the
Diagnosis and Relapse
Prevention
Based on information gained throughout the 6 weeks,
patients are given information about their disorder and
how to cope with the diagnosis in everyday life,
especially regarding communication of information about
the disorder in social situations. Patients are made aware
of possible ways the disorder may progress. It can also
be beneficial to involve relatives in this final session
because they often recognize prodromal symptoms
earlier on than patients.
An emergency plan is created in cooperation with the
patient, which clarifies whom the patient should seek in
case of a crisis (e.g., an institution that the patient trusts,
a therapist). Stress reducing and coping strategies are
discussed. It is also discussed with the patient in which
situations revealing their diagnosis may be helpful or
unhelpful.
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tients’ acceptance was excellent. Most patients eligible
for treatment agreed to participate in the study, although
26 % refused participation. Non-completion rate from a
6-month follow-up of group MCT was 14 % after six
months, although the greatest number of participants
(10 %) dropped out during the first four weeks of the
study (from baseline to the post-treatment follow-up).
Based on this previous work, we anticipate a completion
rate of 80 % for the primary endpoint (T0-T2). See Fig. 1
for a flow chart of the recruitment and study procedure.
Using calculation software PASS 2008 [77] with a con-
ventional alpha level of .05 and a beta-value of .20 for a
two-tailed test, it was calculated that each group must
be comprised of 130 patients to detect a small to
medium effect (d = 0.35) at the 6-month follow-up test-
ing. Assuming a dropout rate of 20 % (including dropout
due to non-compliance and loss to follow-up), the study
will be conducted with a sample size of 328 patients or
82 patients per trial center.
Statistical analyses
Two sets of statistical analyses will be performed. First,
on an intention-to-treat (ITT) basis, which considers all
patients with available baseline data. An expectation
maximization (EM) algorithm will be used to estimate
missing values. The second set of analyses will includeonly participants with baseline and post and/or follow-up
data (per protocol, PP). An ANCOVA model will be con-
ducted with group (MCT+/MyBrainTraining©) difference
between T0 and T1 as the dependent variable. Both treat-
ment (independent of time) and condition*time inter-
action effects will be evaluated. Change scores between T0
and T2 for the primary outcome, as well as analyses over
both time points (T0 vs. T1 and T0 vs. T2) for secondary
endpoints (PANSS syndrome scores, Fish Task, PHQ-9,
CDSS, NSA, WHOQOL-BREF, RSE, BCIS, PSP, neuro-
psychological outcomes), will be tested using analogous
models. Baseline performance or symptoms, antipsychotic
drugs (% of maximum dosage) and concurrent treatment
(e.g., group MCT, individual psychotherapy, and occupa-
tional therapy) will be included in the models as covariates
to explore possible impacts on treatment outcome.
Secondary analyses will be conducted to examine change
between T1 vs. T2 for primary and secondary outcomes.
A logistic regression will be used to analyze variables
that may identify participant response to MCT+, including
severity of baseline psychotic symptoms, level of motiv-
ation for treatment, satisfaction with group assignment,
baseline depression, and number of sessions completed.
Two groups will be defined (criterion: decline of 25 % or
more points on the PSYRATS from T0 to T2) and non-
responders. No interim analyses will be conducted. In a
sensitivity analysis, we will explore the effect of missing
Assessed for eligibility (N = 984)
Excluded (n = 656)
(a screening-to-inclusion ratio of 3:1 is 









Estimated drop out 20% (lost 
to follow-up / discontinuation 
of intervention)
Estimated drop out 20% (lost 
to follow-up / discontinuation 
of intervention)
Analyzed
Per protocol (n = 130)
ITT (n = 164)
Analyzed
Per protocol (n = 130)
ITT (n = 164)
Fig. 1 Study flow
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observation carried forward, last observation carried
forward, full-informational maximum likelihood).
Discussion
This is the first large-scale multi-center trial investigat-
ing the immediate and mid-term effects of the individu-
alized metacognitive therapy program for psychosis
compared to an active control group. Although small to
moderate effects have been found for other psychothera-
peutic interventions, particularly CBTp, implementation
rates of empirically-supported therapies remain low and
a large treatment gap remains for patients with schizo-
phrenia [14, 15, 18]. MCT+ represents an alternative
low-threshold approach, which addresses (mainly) posi-
tive symptoms, but more recently also depression and
self-esteem, which may be able to reach patients who
otherwise may “fall through the cracks” of the healthcare
system [14, 15, 18]. MCT+ may also serve as an add-on
approach for patients who are currently participating in
therapy or are only receiving medication.
Retention and recruitment of patients is a major chal-
lenge for all studies involving individuals with schizo-
phrenia. Many individuals with schizophrenia tend to
feel stigmatized [78, 79], have poor insight [80], be dis-
trustful of care providers [81] and have cognitive limita-
tions, including deficits in memory and executive
functioning [82] that lead to problems remembering ap-
pointments. Therefore, designing a study, in which these
barriers are minimized and patients enjoy participating
is essential. As previously mentioned, MCT and MCT+
are well-accepted by patients [30, 34, 35]; on average, pa-
tients attend 80 % of the MCT+ sessions [34]. In ourmost recent study on group MCT, completion rates at
6 months and 3 years were 86 % and 62 % respectively
[47]. To maximize completion among patients in our con-
trol group, we carefully chose an active intervention (com-
puterized CR), which is designed much like a computer
game. Similar programs have been well-accepted by pa-
tients in previous studies [34, 83]. Nonetheless, to improve
completion rates and enhance memory for material in the
present study, at the end of the 6-week training, we pro-
vide patients in the MCT+ group with a packet of therapy
demonstration sheets that were discussed in therapy ses-
sions. Additionally, patients in both groups are mailed a
postcard three months after completion of the post assess-
ment to remind them of the strategies they learned during
the study. Patients are also reminded both via telephone
and mail of upcoming testing sessions. Many patients are
recruited directly during an inpatient stay and through
outpatient providers, such as therapists and psychiatrists
at the patient's treatment center, which helps to decrease
feelings of distrust since research staff are part of the
patient’s current healthcare facility.
Strengths of this RCT are the large sample size and non-
stringent participation criteria, which aim to improve
generalizability of results (e.g., inclusion of participants
who may meet criteria for alcohol or substance abuse). In
light of research indicating that patient preferences are
often not considered in psychotherapeutic settings and that
mismatch between therapist and patient priorities contrib-
utes to attrition rates (Moritz S, Berna F, Jaeger S,
Westermann S, Nagel M. The customer is always right?
Subjective target symptoms and treatment preferences in
patients with psychosis, submitted), we emphasize the im-
portance of choosing MCT+ units that match the patient’s
Schneider et al. BMC Psychiatry  (2016) 16:51 Page 12 of 14needs. In this way MCT+ is not a “one size fits all” ap-
proach, but rather offers a personalized treatment plan
while maintaining its low-threshold structure. Additionally,
as most trials on MCT and MCT+ have been conducted at
the University Medical Center Hamburg-Eppendorf, inclu-
sion of other study centers will serve to reduce potential al-
legiance effects. Given the “add-on” nature of MCT+,
participants are also allowed to continue routine anti-
psychotic treatment including medication and even group
MCT. However, we carefully monitor treatments that pa-
tients are concurrently participating in, and ask at the be-
ginning of the study which interventions they have
previously participated in. We also do not influence medi-
cation, although information on substances and dosages is
gathered at each testing visit.
The use of MyBrainTraining© as a control condition
prevents the danger of similar interventions in both condi-
tions, which would be the case if CBTp had been chosen.
Similar to other therapy studies, the effect of therapeutic
relationship cannot be completely controlled. Addition-
ally, since all patients are allowed to continue TAU and
many are recruited directly from an inpatient treatment
program, effects of MCT+ may be partially masked for in-
dividuals already receiving intensive comprehensive care.
Conclusions
If MCT+ is shown to be superior to MyBrainTraining©
in reduction of positive symptoms of psychosis, particu-
larly delusional ideation, MCT+ may serve as a valuable
low-threshold therapy for patients and a first step to-
wards comprehensive treatment. Additionally, dissemin-
ation is facilitated as materials in most languages are
available as free downloads via the MCT+ website [75].
As such, this intervention could overcome traditional
treatment barriers to help close the treatment gap for in-
dividuals with psychosis and provide clinicians with an
alternative to therapies, which may be too costly or
time-intensive to routinely implement in daily clinical
practice.
Trial status
The first participant was enrolled in July 2015. At the
time of submission of this study protocol participants
were still being recruited.
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